{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:49:54Z","timestamp":1787237394973,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40123-026-01400-6","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:51:04Z","timestamp":1780311064000},"page":"2337-2349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Utilization and Initial Experience with Aflibercept-ayyh (PAVBLU\u00ae) for Retinal Disorders in United States Retina Practices: A Descriptive Retrospective Analysis"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5523-7767","authenticated-orcid":false,"given":"Argentina E.","family":"Servin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7488-8804","authenticated-orcid":false,"given":"Ian","family":"McFadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houri","family":"Esmaeilkhanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Holcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-9722","authenticated-orcid":false,"given":"Carl C.","family":"Awh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"15","key":"1400_CR1","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1001\/jama.290.15.2057","volume":"290","author":"NG Congdon","year":"2003","unstructured":"Congdon NG, Friedman DS, Lietman T. Important causes of visual impairment in the world today. JAMA. 2003;290(15):2057\u201360.","journal-title":"JAMA"},{"issue":"4","key":"1400_CR2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s11892-012-0283-6","volume":"12","author":"J Ding","year":"2012","unstructured":"Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012;12(4):346\u201354.","journal-title":"Curr Diab Rep"},{"key":"1400_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.","journal-title":"Eye Vis (Lond)"},{"issue":"10153","key":"1400_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. Lancet. 2018;392(10153):1147\u201359.","journal-title":"Lancet"},{"issue":"1","key":"1400_CR5","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.09.010427","volume":"9","author":"P Song","year":"2019","unstructured":"Song P, Xu Y, Zha M, Zhang Y, Rudan I. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors. J Glob Health. 2019;9(1):010427.","journal-title":"J Glob Health"},{"issue":"7","key":"1400_CR6","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s00417-017-3647-4","volume":"255","author":"P Lanzetta","year":"2017","unstructured":"Lanzetta P, Loewenstein A, Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259\u201373.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"1400_CR7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"issue":"11","key":"1400_CR8","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247\u201354.","journal-title":"Ophthalmology"},{"issue":"1","key":"1400_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: one-year results of the phase\u00a03 GALILEO study. Ophthalmology. 2014;121(1):202\u20138.","journal-title":"Ophthalmology"},{"key":"1400_CR10","doi-asserted-by":"crossref","unstructured":"Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155(3):429\u2013437.e7.","DOI":"10.1016\/j.ajo.2012.09.026"},{"key":"1400_CR11","unstructured":"PAVBLU\u00ae (aflibercept-ayyh). Prescribing information. Amgen Inc. 2026. https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/pavblu\/pavblu_fpi_english.pdf. Accessed Feb 19, 2026."},{"key":"1400_CR12","doi-asserted-by":"crossref","unstructured":"Friedman S, London N, Hamouz J, et al. Randomized trial of biosimilar ABP 938 compared with reference aflibercept in adults with neovascular age-related macular degeneration. Ophthalmol Retina. 2026;10(2):152\u2013164.","DOI":"10.1016\/j.oret.2025.07.015"},{"issue":"5","key":"1400_CR13","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s40123-024-00914-1","volume":"13","author":"N Seo","year":"2024","unstructured":"Seo N, Guan X, Wang T, et al. Analytical and functional similarity of aflibercept biosimilar ABP 938 with aflibercept reference product. Ophthalmol Ther. 2024;13(5):1303\u201320.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1400_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40123-024-01043-5","volume":"14","author":"N Seo","year":"2025","unstructured":"Seo N, Kuhns S, Andrews DA, Colbert A, Chow V, Liu J. Nonclinical similarity of the biosimilar candidate ABP 938 with aflibercept reference product. Ophthalmol Ther. 2025;14(1):85\u2013101.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1400_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","volume":"94","author":"FL Ferris 3rd","year":"1982","unstructured":"Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94(1):91\u20136.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1400_CR16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40942-021-00358-w","volume":"8","author":"A Miller","year":"2022","unstructured":"Miller A, Wilneff MA, Yazji A, et al. Analysis of urgent follow up visits and complications after intravitreal injections: a retrospective cohort study. Int J Retina Vitreous. 2022;8(1):8.","journal-title":"Int J Retina Vitreous"},{"issue":"April","key":"1400_CR17","first-page":"27","volume":"19","author":"E Fleissig","year":"2022","unstructured":"Fleissig E, Loewenstein A. Complications of intravitreal injections. Incidence is low, but caution is warranted. Retin Physician. 2022;19(April):27\u20139.","journal-title":"Retin Physician"},{"key":"1400_CR18","doi-asserted-by":"crossref","unstructured":"Sharma A, Nicholson L, Vazquez-Alfageme C, et al. FYB-201 biosimilar ranibizumab (Ongavia\/Ranivisio\/Cimerli) efficacy and safety in clinical settings\u2014FORCE study. Eye (Lond). 2025;39(17):3129\u201334.","DOI":"10.1038\/s41433-025-04030-7"},{"issue":"16","key":"1400_CR19","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1038\/s41433-024-03220-z","volume":"38","author":"T Ueda-Consolvo","year":"2024","unstructured":"Ueda-Consolvo T, Ishida M, Nakamura T, et al. Biosimilar ranibizumab (BS1)\u2014early experience from Japan (BRIJ study). Eye (Lond). 2024;38(16):3193\u20136.","journal-title":"Eye (Lond)"},{"issue":"3","key":"1400_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40123-020-00277-3","volume":"9","author":"S Sharma","year":"2020","unstructured":"Sharma S, Group R-ESI, Khan M, Chaturvedi A. A multicenter, retrospective study (RE-ENACT 2) on Razumab (world\u2019s first biosimilar ranibizumab) in retinal vein occlusion. Ophthalmol Ther. 2020;9(3):625\u201339.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"1400_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40123-019-00228-7","volume":"9","author":"S Sharma","year":"2020","unstructured":"Sharma S, Khan M, Chaturvedi A, Group R-ESI. A multicenter, retrospective study (RE-ENACT 2) on the use of Razumab (world\u2019s first biosimilar ranibizumab) in wet age-related macular degeneration. Ophthalmol Ther. 2020;9(1):103\u201314.","journal-title":"Ophthalmol Ther"},{"key":"1400_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/24741264251322213","author":"A Sharma","year":"2025","unstructured":"Sharma A, Holz FG, Kumar N, et al. Biosimilar ranibizumab (Ranieyes) safety and efficacy in the real world: BRESER study. J Vitreoretin Dis. 2025. https:\/\/doi.org\/10.1177\/24741264251322213.","journal-title":"J Vitreoretin Dis"},{"issue":"5","key":"1400_CR23","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41433-024-03370-0","volume":"39","author":"KYC Teo","year":"2025","unstructured":"Teo KYC, Eldem B, Joussen A, et al. Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration. Eye (Lond). 2025;39(5):860\u20139.","journal-title":"Eye (Lond)"},{"issue":"3","key":"1400_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40123-021-00350-5","volume":"10","author":"J Carrasco","year":"2021","unstructured":"Carrasco J, Daien V, Eldem BM, Spoorendonk JA, Yoon J. 2-Year real-world outcomes with intravitreal aflibercept in neovascular age-related macular degeneration: literature review and meta-analysis of patient-relevant outcomes. Ophthalmol Ther. 2021;10(3):397\u2013411.","journal-title":"Ophthalmol Ther"},{"issue":"8","key":"1400_CR25","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s00417-020-05059-y","volume":"259","author":"E Granstam","year":"2021","unstructured":"Granstam E, Aurell S, Sjovall K, Paul A. Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting. Graefes Arch Clin Exp Ophthalmol. 2021;259(8):2085\u201393.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"1400_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-022-00373-5","volume":"8","author":"AE Sepetis","year":"2022","unstructured":"Sepetis AE, Clarke H, Gupta B. Functional and structural characteristics in patients with diabetic macular oedema after switching from ranibizumab to aflibercept treatment. Three year results in real world settings. Int J Retina Vitreous. 2022;8(1):23.","journal-title":"Int J Retina Vitreous"},{"issue":"8","key":"1400_CR27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/bjo-2024-326152","volume":"109","author":"E Borrelli","year":"2025","unstructured":"Borrelli E, Foti C, Ulla L, et al. Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration. Br J Ophthalmol. 2025;109(8):875\u201381.","journal-title":"Br J Ophthalmol"},{"key":"1400_CR28","doi-asserted-by":"crossref","unstructured":"Lakhani M, Kwan ATH, Kundapur D, Popovic MM, Damji KF, Hurley BR. Association of anti-VEGF therapy with reported ocular adverse events: a global pharmacovigilance analysis. Ophthalmol Retina. 2026;10(3):265\u201382.","DOI":"10.1016\/j.oret.2025.08.018"},{"key":"1400_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1017889","volume":"13","author":"P Ma","year":"2022","unstructured":"Ma P, Pan X, Liu R, et al. Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA adverse event reporting system (FAERS). Front Pharmacol. 2022;13:1017889.","journal-title":"Front Pharmacol"},{"key":"1400_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2147\/OPTH.S393519","volume":"17","author":"U Schmidt-Ott","year":"2023","unstructured":"Schmidt-Ott U, Fitzpatrick S, Hasanbasic Z, et al. Reported rates of intraocular inflammation with intravitreal Aflibercept administered via pre-filled syringe or from vials in clinical practice between 2012 and 2022. Clin Ophthalmol. 2023;17:385\u201390.","journal-title":"Clin Ophthalmol"},{"key":"1400_CR31","unstructured":"EYLEA\u00ae (aflibercept) injection. Prescribing information. Regeneron Pharmaceuticals, Inc. 2026. https:\/\/www.regeneron.com\/downloads\/eylea_fpi.pdf. Accessed Feb 19, 2026."},{"issue":"2","key":"1400_CR32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ajo.2011.01.053","volume":"152","author":"S Day","year":"2011","unstructured":"Day S,\u00a0Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011;152(2):266\u201372.","journal-title":"Am J Ophthalmol"}],"updated-by":[{"DOI":"10.1007\/s40123-026-01481-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000}}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01400-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01400-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01400-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:10:49Z","timestamp":1787235049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01400-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1400"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01400-6","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to incorrect table 3.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40123-026-01481-3","URL":"https:\/\/doi.org\/10.1007\/s40123-026-01481-3","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Argentina E. Servin and Ian McFadden are employees and stockholders of Amgen Inc. Houri Esmaeilkhanian and Diana Holcomb are employees of RCA. James Lin is an employee of Vitreoretinal Consultants of New York. Carl C. Awh is an employee of Tennessee Retina. The sponsor contributed to the study design and participated as a collaborator in the data analysis. The authors retained full access to the data and were responsible for the interpretation of the results. All analyses were conducted collaboratively, with the authors maintaining independent scientific judgment throughout. Safety data were collected independently of the sponsor. Adverse events of scientific interest were adjudicated by physicians who were independent of the sponsor, ensuring objective evaluation. The authors maintained full control over the content of the manuscript, including the interpretation of findings and the conclusions presented. The decision to submit the manuscript for publication was made by the authors in agreement with the sponsor. The sponsor was provided the opportunity to review the manuscript for scientific accuracy; however, the authors retained final authority over the content and submission.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed by an independent external institutional review board (IRB), Advarra, and was determined to be exempt from IRB oversight (determination date June 17, 2025) due to its use of de-identified data collected during routine clinical care. Informed consent was not required. The study was conducted in accordance with applicable regulatory requirements and the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}